Results 121 to 130 of about 728 (161)

Abstract 4368742: Long-term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM

Circulation
Introduction: Treatment with aficamten in patients with obstructive HCM (oHCM) led to significant improvements in patient-reported outcomes (PROs) over 24 weeks in the pivotal SEQUOIA-HCM trial.
Shepard Weiner, Lusha Liang, Ahmad Masri, T. Abraham, R. Barriales-Villa, R. Cooper, P. Elliott, Alejandro de Feria, M. Maron, A. Oręziak, S. Saberi, Scott D. Solomon, J. Spertus, Albree Tower Rader, Michael Butzner, S. Heitner, D. Jacoby, S. Kupfer, Xueli Liu, F. Malik, C. Melloni, Tyrell Simkins, Jenny Wei, M. Nassif, Anjali Owens   +24 more
semanticscholar   +1 more source

Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.

Journal of the American College of Cardiology
BACKGROUND The cardiac myosin inhibitor aficamten was significantly more effective than metoprolol at improving exercise tolerance in MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a head-to-head ...
M. Nassif, P. García-Pavía, Ahmad Masri, B. Merkely, M. L. Peña-Peña, R. Barriales-Villa, Ozlem Bilen, Melissa Burroughs, B. Claggett, J. Costabel, Edileide de Barros Correia, A. Dybro, P. Elliott, Neal K Lakdawala, G. Lewis, Amy Mann, Martin S. Maron, Z. Miao, Ajith Nair, S. Poulsen, P. Reant, P. Schulze, Scott D. Solomon, Andrew Wang, R. Sohn, I. Berhane, S. Heitner, D. Jacoby, S. Kupfer, F. Malik, A. Wohltman, M. Fifer, J. Spertus   +32 more
semanticscholar   +1 more source

Innovative pharmacological approaches to hypertrophic cardiomyopathy: The emerging role of Aficamten

Current Problems in Cardiology
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by left ventricular hypertrophy (LVH), which can lead to left ventricular outflow tract (LVOT) obstruction. Traditional treatments often provide limited symptom relief and may not adequately reduce the LVOT gradient.
Emmanuel, Kokori, Ravi, Patel, Gbolahan, Olatunji, Abdulbasit Opeyemi, Muili, Victor Oluwatomiwa, Ajekiigbe, Abdulrahmon, Moradeyo, Adetola Emmanuel, Babalola, Julia Mimi, Kwape, Oluwatobi, Omoworare, Nicholas, Aderinto   +9 more
openaire   +2 more sources

Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.

Journal of the American College of Cardiology
BACKGROUND For >60 years, beta-blockers have been first-line therapy for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), although limited data support this recommendation.
Andrew Wang, P. García-Pavía, Ahmad Masri, B. Merkely, M. Nassif, M. L. Peña-Peña, R. Barriales-Villa, Ozlem Bilen, Melissa Burroughs, B. Claggett, J. Costabel, Edileide de Barros Correia, A. Dybro, P. Elliott, S. M. Hegde, I. Kulac, Neal K Lakdawala, G. Lewis, Amy Mann, Ajith Nair, S. Poulsen, P. Reant, P. Schulze, Scott D. Solomon, R. Sohn, I. Berhane, S. Heitner, D. Jacoby, S. Kupfer, F. Malik, A. Wohltman, M. Fifer, Martin S. Maron   +32 more
semanticscholar   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: A Head-to-Head Network Meta-Analysis of Mavacamten and Aficamten

Bioscientia Medicina : Journal of Biomedicine and Translational Research
Background: Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by myocardial hypercontractility. Mavacamten and aficamten are first-in-class cardiac myosin inhibitors that have demonstrated efficacy in treating obstructive HCM. However,
Network Meta-Analysis of, Mavacamten Aficamten, Imran Saleh, Syamsu Indra, Y. D. Andayani, Rukiah Chodilawati   +5 more
semanticscholar   +1 more source

A summary of results from SEQUOIA-HCM: A clinical study of aficamten for obstructive hypertrophic cardiomyopathy

Video Journal of Biomedicine
This video explains key findings from the SEQUOIA-HCM trial, which were published in the New England Journal of Medicine. SEQUOIA-HCM focuses on obstructive hypertrophic cardiomyopathy (or oHCM), a condition where the heart contracts too strongly and the
M. Maron, I. Olivotto, Marion van Sinttruije   +2 more
semanticscholar   +1 more source

A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin

International journal of toxicology
Aficamten (CK-3773274) is a cardiac myosin inhibitor in development for the treatment of hypertrophic cardiomyopathy (HCM), a commonly inherited heart condition often characterized as a disease of the sarcomere.
M. Pugsley, D. Hwee, Brett R. Winters, Jingying Wang, Eva R Chin, Bradley P. Morgan, F. Malik   +6 more
semanticscholar   +1 more source

Synthesis of Aficamten

Synfacts, 2021
openaire   +1 more source

Aficamten versus Metoprolol in Obstructive Hypertrophic Cardiomyopathy: Recent Analyses of the MAPLE-HCM Trial

EMJ Cardiology
This article is based on presentations of a late breaking clinical trial at the European Society of Cardiology (ESC) Congress in conjunction with the World Congress of Cardiology (WCC), which took place between 29th August–1st September 2025 in Madrid ...
Rachel Danks
semanticscholar   +1 more source

Abstract 4370461: Aficamten is safe and effective in oHCM with comorbidities obesity, hypertension, and diabetes: a SEQUOIA-HCM sub-study

Circulation
Introduction/Background: Obesity, hypertension, and diabetes commonly coexist with obstructive hypertrophic cardiomyopathy (oHCM), potentially influencing symptom burden and functional limitation.
M. Lee, T. Abraham, B. Claggett, M. Maron, Z. Miao, B. Meder, I. Olivotto, S. Heitner, D. Jacoby, F. Malik, S. Kupfer, A. Wohltman, C. Coats   +12 more
semanticscholar   +1 more source